CMC
薬事
非臨床
Susan has over 24 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Prior to joining BCVG in 2022, Susan led product development, regulatory, preclinical, and program management at Sigilon Therapeutics, a cell therapy company combining biomaterials and cellular engineering to treat rare diseases. Previously, she served as the Senior Director of Business Development and Strategy at Vericel Corporation, and before that, spent 14 years at Medtronic Spine running part of the Biologics product development organization as well as leading due diligence efforts. While at Medtronic, her team launched numerous products, submitted INDs, supported manufacturing and more. Earlier in her career, she worked at Osiris Therapeutics with Dr. Bruder, leading allogeneic cell therapies in orthopedics. Dr. Drapeau serves as an advocate for the biomedical field as part of AIMBE, and sits on the Advisory Board for the Department of Biomedical Engineering at Rice University. Susan is a graduate of Purdue University (BS, Chemical Engineering and BS, Chemistry) and Rice University (PhD, Chemical Engineering).
Bruder Consulting and Venture Group
Vice President
Sigilon Therapeutics, Inc.
Chief, Preclinical Operations Officer
Senior VP, Head of Preclinical Development
VP, Head of Preclinical Development
Vericel® Corporation
Senior Director, Business Development and Strategy
Medtronic
Director, Biologics R&D and Medtronic Technical Fellow
Senior Manager, Biologics R&D
Manager, Biologics R&D
Biologic Project Leader
Osiris Therapeutics
Sr. Manager, Bone Products
Manager, Bone Products
Research Engineer I/II
Rice University
Ph.D., Chemical Engineering
Purdue University
BS, Chemistry
BS, Chemical Engineering
